22 research outputs found
Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin
Background: Trastuzumab has revolutionized treatment of HER2+ breast cancer. Globally accessible alternatives are a critical need. We evaluated Myl-1401O, a proposed trastuzumab biosimilar, as treatment for HER2+ metastatic breast cancer (MBC), based on physicochemical analyses, nonclinical, pharmacokinetic and pharmacodynamic studies*. Methods: Heritage is a double-blind, randomized clinical trial designed to evaluate comparative efficacy and safety of Myl-1401O vs Herceptin. Eligible patients (pts) had ..
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer. A Randomized Clinical Trial
IMPORTANCE Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab
and chemotherapy significantly improves outcome in patients with ERBB2 (HER2)–positive
metastatic breast cancer; a clinically effective biosimilar may help increase access to this therapy.
OBJECTIVE To compare the overall response rate and assess the safety of a proposed
trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without prior
treatment for ERBB2-positive metastatic breast cancer.
DESIGN, SETTING, AND PARTICIPANTS Multicenter, double-blind, randomized, parallel-group,
phase 3 equivalence study in patients with metastatic breast cancer. From December 2012 to
August 2015, 500 patients were randomized 1:1 to receive a proposed biosimilar or
trastuzumab plus a taxane. Chemotherapy was administered for at least 24 weeks followed
by antibody alone until unacceptable toxic effects or disease progression occurred.
INTERVENTIONS Proposed biosimilar (n = 230) or trastuzumab (n = 228) with a taxane.
MAIN OUTCOMES AND MEASURES The primary outcome was week 24 overall response rate
(ORR) defined as complete or partial response. Equivalence boundaries were 0.81 to 1.24
with a 90% CI for ORR ratio (proposed biosimilar/trastuzumab) and −15% to 15% with a 95%
CI for ORR difference. Secondary outcome measures included time to tumor progression,
progression-free and overall survival at week 48, and adverse events.
RESULTS Among 500 women randomized, the intention-to-treat population included 458
women (mean [SD] age, 53.6 [11.11] years) and the safety population included 493 women.
The ORR was 69.6% (95% CI, 63.62%-75.51%) for the proposed biosimilar vs 64.0% (95% CI,
57.81%-70.26%) for trastuzumab. The ORR ratio (1.09; 90% CI, 0.974-1.211) and ORR difference
(5.53; 95% CI, −3.08 to 14.04) were within the equivalence boundaries. At week 48, there was no
statistically significant difference with the proposed biosimilar vs trastuzumab for time to tumor
progression (41.3% vs 43.0%; −1.7%; 95% CI, −11.1% to 6.9%), progression-free survival (44.3%
vs 44.7%; −0.4%; 95% CI, −9.4% to 8.7%), or overall survival (89.1% vs 85.1%; 4.0%; 95% CI,
−2.1% to 10.3%). In the proposed biosimilar and trastuzumab groups, 239 (98.6%) and 233
(94.7%) had at least 1 adverse event, the most common including neutropenia (57.5% vs 53.3%),
peripheral neuropathy (23.1% vs 24.8%), and diarrhea (20.6% vs 20.7%).
CONCLUSIONS AND RELEVANCE Among women with ERBB2-positive metastatic breast cancer
receiving taxanes, the use of a proposed trastuzumab biosimilar compared with trastuzumab
resulted in an equivalent overall response rate at 24 weeks. Further study is needed to assess
safety and long-term clinical outcome.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT02472964; EudraCT Identifier:
2011-001965-4
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
The article presents the experience of 19 Russian medical institutions on the use of eribulin in combination with trastuzumab in various treatment lines of metastatic HER2+ breast cancer in routine clinical practice.
Aim. The main objective of this retrospective observational study was to evaluate the efficacy and tolerability of eribulin and trastuzumab combo in HER2+ breast cancer patients pretreated with anthracyclines and taxanes. The analysis included 60 patients who received at least 2 cycles of eribulin in combination with trastuzumab. 2 patients (3.3%) received treatment as the 1st line, as the 2nd 14 (23.3%), as the 3rd 16 (26.7%), and as the 4th and more 28 (46.7%).
Materials and methods. Complete response was achieved in 2 (3.3%) patients, partial response in 9 (15%), stable disease in 33 (55%), stabilization for more than 6 months in 11 (18.3%), disease progression was detected in 16 (26.7%) patients. The objective response rate was 18.3% in the whole group, the clinical benefit rate 36.7%.
Results. The objective response rate in the group of the luminal subtype (ER/PR+HER2+) was 26.9%, in HER2-overexpressed subtype (ER-PR-HER2+) 8.8% and 64.7%, respectively, disease progression was recorded 2.3 times more often 35.3% versus 15.5% in the luminal subtype group. The median progression-free survival in patients with HER2+ breast cancer was 4.95 months (95% confidence interval CI 3.048.29 months), in luminal subtype 6.38 months (95% CI 3.338.54 months), in non-luminal 4.44 months (95% CI 2.47.96 months); p=0.306. The treatment was well tolerated, the spectrum of adverse events corresponded to the eribulin toxicity profile.
Conclusions. The uniqueness of this study lies in the fact that on a large clinical material from the standpoint of real clinical practice, a very promising treatment regimen that is not used routinely in a number of countries has been studied, its effectiveness and satisfactory tolerance have been confirmed
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
PrefHer revealed compelling and consistent patient preference for subcutaneous (s.c.) trastuzumab, regardless of delivery by single-use injection device or hand-held syringe. s.c. trastuzumab was well-tolerated and safety data, including immunogenicity, were consistent with previous reports. No new safety signals were identified compared with the known intravenous trastuzumab profile in early breast cance
Analysis of the Aspen Growth (Populus tremula L.) Obtained by in Vitro in the Republic of Tatarstan
The paper presents the results of an experiment on the propagation of aspen clones (Populus tremula L.) of diploid and triploid genotypes resistant to pith rot by methods of microclonal reproduction and their introduction into forestry production in the Republic of Tatarstan. The expediency of using this method for obtaining healthy aspen planting material has been substantiated, and the prospects for the reproduction of clone No. 35 with a triploid genotype have been shown